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Abstract
Background: This study assessed clinical outcomes, including safety and recurrence, from the two-year follow-up
of patients who underwent open ventral primary hernia repair with the use of the Parietex™ Composite Ventral
Patch (PCO-VP).
Methods: A prospective single-arm, multicenter study of 126 patients undergoing open ventral hernia repair for
umbilical and epigastric hernias with the PCO-VP was performed.
Results: One hundred twenty-six subjects (110 with umbilical hernia and 16 with epigastric hernia) with a mean hernia
diameter of 1.8 cm (0.4–4.0) were treated with PCO-VP. One hundred subjects completed the two-year study.
Cumulative hernia recurrence was 3.0% (3/101; 95%CI: 0.0–6.3%) within 24months. Median Numeric Rating Scale pain
scores improved from 2 [0–10] at baseline to 0 [0–3] at 1 month (P < 0.001) and remained low at 24months 0 [0–6]
(P < 0.001). 99% (102/103) of the patients were satisfied with their repair at 24months postoperative.
Conclusions: The use of PCO-VP to repair primary umbilical and epigastric defects yielded a low recurrence rate, low
postoperative and chronic pain, and high satisfaction ratings, confirming that PCO-VP is effective for small ventral
hernia repair in the two-year term after implantation.
Trial registration: The study was registered publically at clinicaltrials.gov (NCT01848184 registered May 7, 2013).
Keywords: Ventral hernia, Epigastric hernia, Umbilical hernia, Intraperitoneal mesh, Surgical mesh, Parietex™ composite
ventral patch
Background
Although there is no consensus on the ideal technique for
repairing umbilical or epigastric hernias in adults, to our
knowledge only two prospective randomized trials have
been conducted. The first by Arroyo et al. showed an 11%
versus 1% recurrence rate after primary suture and mesh
repair [1]. While the second, by Polat et al. compared 3
different techniques in umbilical hernia repairs (Prolene
Hernia System, Mayo repair, and onlay repair with mesh)
and demonstrated recurrence rates of 0, 11, and 0%, re-
spectively [2]. According to Arroyo et al. and also retro-
spectively shown by Sanjay et al., the conclusion could be
drawn that the use of mesh in these patients is mandatory,
no matter the diameter of the defect [3]. Due to the tech-
nical difficulty of retrorectus and preperitoneal dissection
for these small hernias, an alternative approach is to use a
self expanding mesh device that can be introduced via an
incision at the level of the hernia into the peritioneal cav-
ity. Once deployed, traction on the fixation points or
straps leads to a flat alignment to the abdominal wall. As a
quick and elegant procedure, these devices have been em-
braced by many surgeons.
However, further studies on the two most frequently
used mesh devices revealed several issues influencing
clinical outcomes. Cases of serious complications due to
severe adhesion formation as well as higher recurrence
rates compared to traditional retromuscular mesh place-
ment have been reported [4–6]. Thus, in addition to the
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design of the mesh device, adequate handling of the fatty
intra-abdominal structures (both falciform ligament and
umbilical folds) is mandatory to achieve best outcomes.
The currently available devices for repair of small ventral
hernias consist of polypropylene (PP) in combination
with well known anti-adhesive barriers, as ePTFE, sepra-
mesh technology or oxidized cellulose.
Several earlier reports also mention issues with deploy-
ment using a two-strap fixation method [4, 7]. Instead,
by using a four-flap fixation, flat alignment to the ab-
dominal wall might be improved. This manuscript re-
ports the final two-year clinical results of a prospective
study of patients undergoing open ventral hernia repair
with intra-peritoneal positioning of a recently developed
patch for hernia repair.
Methods
As reported in the early results of this prospective
multicenter cohort study, patients underwent a small
primary ventral hernia repair using the Parietex™
Composite Ventral Patch (PCO-VP) (Medtronic; Tre-
voux, France) with a diameter of 4.6, 6.6, or 8.6 cm,
depending on the size of the defect [8]. The objec-
tives were to assess hernia recurrence at 24 months
follow-up and safety. All patients ≥18 years of age
planned for primary ventral hernia surgery via open
approach were consented if they met eligibility cri-
teria via a screening/baseline visit within 6 weeks of
their procedure. All in- and exclusion criteria were
reported previously with patients in need of emer-
gency surgery, pregnant patients and BMI > 35 kg/m2
being excluded. The surgical procedure applied was
described in detail earlier [9]. In short, opening of the
hernia sac was performed, and the fascial defect was
measured. The sac was dissected out and opened and
possible contents were reduced. A finger was then
inserted into the defect to clear the surrounding peri-
toneum. The PCO-VP was then inserted into the
peritoneal cavity. After introduction, the mesh is
pulled up gently, to flatten the patch against the ab-
dominal wall. To fix the mesh against the abdominal
wall the 4 quadrants of the patch were fixed to the
margins of the fascia defect with 4 non-resorbable su-
tures. Although not specifically recommended, the an-
terior fascia was then closed over the mesh to
minimize the risks for mesh infection. For hernias <
1 cm in diameter any size of PCO-VP could be used.
For hernias 1–3 cm in diameter, 6.6 and 8.6 cm PCO-
VP were recommended, and for hernias > 3 cm in
diameter, 8.6 cm PCO-VP was recommended. The
meshes were deployed in the intraperitoneal position.
If intraperitoneal positioning was difficult, preperito-
neal placement was performed. Laparoscopic control
was only performed in 10 patients as described earlier
[8], all other patients had no laparoscopy done at the
end of the procedure.
The primary endpoint was recurrence at 24 months
evaluated by a physical examination and by ultrasonog-
raphy in all patients (not only in case of suspicion for re-
currence). The secondary endpoints were recurrence at
one, six- and 12-months post-surgery. Additional out-
comes included: postoperative pain measured by the Nu-
meric Rating Scale (NRS) 0–10 in accordance with the
definition in 4 categories (0 = No pain, 1–3 =minor/mild
pain, 4–6 =moderate pain, 7–9 = severe pain, and 10 =
worst pain); postoperative patient comfort measured by
the Carolina’s Comfort Scale® (CCS) to assess quality of
life, as well as adverse events (AEs).
Statistics
As the recurrence rate for primary ventral hernia repair
using synthetic mesh is approximately 4% (range: 0–6%)
[5, 7–10], assuming a 95% confidence interval, 60 pa-
tients were needed for the evaluable population. Antici-
pating a 20% lost to follow-up rate a minimum of 100
patients were required as the evaluable population. Re-
currence rates and complications were analyzed using
time to event (Kaplan-Meier) analysis, while Student t-
test or non-parametric Mann-Whitney test were used
for mean comparisons between sub-groups. Proportion
comparisons between sub-groups were performed using
Chi-square or Fisher’s exact test. All tests were per-
formed using two-side tests with an α-level of 5%. Ana-
lyses were performed using SAS® Version 9.2 or higher
(SAS Inc., Cary, NC).
This study was conducted in accordance with the Dec-
laration of Helsinki (2008), ICH–GCP guidelines, ISO
14155-2011, institutional review board, and ethics coun-
cil approval. The study was registered publically at clini-
caltrials.gov (NCT01848184).
Results
One hundred twenty-six patients, including 87 males
and 39 females, were enrolled between May 3, 2013 and
July 12, 2016 and treated by 12 surgeons in 12 different
centers in Europe and the United States. A total of 110
(87.3%) patients were assessed at 12 months and 100
(79.4%) patients were assessed at 24 months for hernia
recurrence and completed the two-year clinical assess-
ment for the primary endpoint. Three additional patients
were assessed by phone at the 24-month follow-up.
Most patients who exited the study before 24 months
were lost to follow-up (9.5%, n = 12/126), withdrew vol-
untarily (6.3%, n = 8/126), were unable or unwilling to
participate in follow-up visits (2.4%, n = 3/126), exited
due to AEs (1.6%, n = 2/126), or death (0.8%, n = 1/126)
that was not procedure or device related. Most patients
(n = 110) were treated for an umbilical hernia and the
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remainder (n = 16) were treated for epigastric hernia.
Forty-three (34.1%, n = 43/126) patients had a BMI of at
least 30 kg/m2, and 90 (71.4%, n = 90/126) patients had
at least one risk factor at baseline, including smoking
(42.9%, n = 54/126), type II diabetes (7.9%, n = 10/126),
and chronic obstructive pulmonary disease (7.1%, n = 9/
126). The median operative time was 33min [range, 10–
93min].
In total, 3 hernia recurrences (3.0%, n = 3/101); 95%CI:
0.0–6.3%) occurred within 2 years of repair (79 days, 197
days, and 288 days after surgery) including one patient
who withdrew from the study after recurrence at 79 days.
Reoperations were performed for two patients: A 33-year
old female with BMI of 22.6 kg/m2 who had received an
8.6 cm PCO-VP for a 2.2 cm umbilical hernia repair expe-
rienced a hernia recurrence 79 days after surgery. A phys-
ical exam and ultrasound confirmed the recurrence. A
laparoscopic reoperation confirmed a probable missed
second hernia defect cephalad to the PCO-VP. Extensive
adhesiolysis from omentum and colon was necessary to
identify the defect and the PCO-VP prosthesis was re-
moved. A 15 × 19 cm piece of mesh was placed intraperi-
toneally. The second patient was a 54-year old male with
BMI of 28.4 kg/m2 who underwent umbilical hernia repair
for a 3 cm hernia with an 8.6 cm PCO-VP. This subject
experienced a hernia recurrence 197 days after surgery
and eventually underwent laparoscopy demonstrating 50%
cupping of the PCO-VP causing the recurrence, and an
open preperitoneal repair with a 9 × 16 cm mesh was per-
formed leaving the PCO-VP in place. The third patient
with recurrence was a 69-year old female patient with a
BMI of 34.7 kg/m2 who had a recurrence at 288 days. Her
1.2 cm umbilical hernia had been repaired by preperito-
neal mesh placement using a 4.6 cm PCO-VP. During the
original repair, the surgeon had difficulty with the intra-
peritoneal dissection and the mesh was placed preperito-
neally rather than intraperitoneally mainly due to the
patient’s obesity. Reoperation for the recurrence was not
performed as it was asymptomatic.
Throughout the two-year study, 51 (40.5%, n = 51/126)
subjects experienced at least 1 single AE, including 26
incidents (32.1%) of device-related AE, 54 incidents
(66.7%) of procedure-related AE, and a total of 30 inci-
dents (37%) of serious AE (SAEs). Twelve patients (9.5%,
n = 12/126) had 2 AEs, 6 (4.8%, n = 6/126) patients had 3
AEs, and 2 (1.6%, n = 2/126) patients had 4 AEs. Table 1
describes the number of patients who reported proced-
ure or device related AEs.
Postoperative numeric rating scale (NRS) pain scores
are depicted in Fig. 1. Scores improved from a median
[min-max] of 2 [0–10] at baseline to 0 at 24months [0–6].
At baseline 34/120 (28.3%) patients experienced no pain.
These values improved to 77/123 (62.6%) at 1 month and
96/103 (93.2%) at 24months. Global Carolina’s™ Comfort
Scale score improved from 1 [0–36] at 1month postoper-
ative to 0 [0–39] (P < 0.001) at 2 years post-surgery. When
patients were asked to rate their satisfaction with the out-
come of their procedure, the vast majority of patients
responded as “completely satisfied” at all points of assess-
ment, and 99% (102/103) of patients were satisfied with
their repair at 24months postoperative (Fig. 2). One pa-
tient responded as “unsatisfied” at his last assessment—he
was the patient with hernia recurrence at 197 days.
Discussion
Until now the use of different mesh devices has led to
unacceptable morbidity, including gastrointestinal ob-
structions, mesh erosions, as well as high recurrence
rates compared to other types of repair. In the present
study more than 100 patients with umbilical hernia and
epigastric hernia repair using the PCO-VP were investi-
gated over the course of 2 years. Historically, these types
of hernias, with relatively small defect diameters be-
tween 0.5 cm and 3 cm, have been primarily repaired
using either suture closures, or the Mayo technique,
yielding recurrence rates of 10–30% [10, 11]. As evident
from this and similar studies, the use of a prosthetic
mesh significantly reduces the mid-term 2 year rates of
hernia recurrence even for small defects [1, 12, 13]. Re-
currence rates of up to 2.2% (range, 1–2.2%) have previ-
ously been demonstrated using the mesh repair [1, 13]
and similarly our study yielded a cumulative hernia re-
currence rate of 3.0% within 24months. With PCO-VP,
the most common AEs reported were pain between dis-
charge and 1-month follow-up (n = 27, 21.4%), and
superficial wound dehiscence (n = 5, 4.0%). Pre-existing
risk factors did not predispose subjects to AEs, although
obesity might complicate mesh introduction in the intra-
peritoneal position as observed in 1 patient, which was
later complicated by a recurrence.
Table 1 Summary of incidence of specified AEs from baseline
through 24-month follow-up
N = 126
Subject with at least 1 AE 51 (40.5%)
Pain 27 (21.4%)
Abdominal pain due to recurrence 1 (0.8%)
Wound infection 5 (4.0%)
Hernia recurrence 3 (2.4%)
Haematoma at incision site 2 (1.6%)
Seroma 2 (1.6%)
Othera 5 (4.0%)
Data are presented in number of subjects, n (%). aOther includes anemia
1(0.8%), occasional feeling of tightness at the operative site 1(0.8%), serious
drainage at incision site 1(0.8%), Skin irritation 1(0.8%), and puncture of small
bowel 1(0.8%)
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The cupping phenomenon or “potato-chip” deform-
ities are well-known issues after the use of mesh devices
for small ventral hernia repair. These complications are
probably due to excessive traction on the straps in order
to align the patch flatly against the parietal peritoneum
[4, 7]. Although mesh misalignment may also have oc-
curred in this series [8], as laparoscopic evaluation is the
only way to verify this, the low recurrence (3%) and re-
operation rate observed at the end of the 2 year follow
up, show that at least the clinical impact of misalign-
ment has been minimal. Nevertheless, accurate surgical
technique with complete dissection of the falciform liga-
ment cranially and the umbilical folds caudally is
mandatory to obtain best patient outcomes, especially
when using the largest 8.6 cm patch. Garcia-Moreno et
al. specifically examined the prothetic design of PCO-VP,
in which the authors concluded, that both the
intraperitoneal positioning and the incorporation of the
mesh in the abdominal wall were very reliable using the
four flap handles and fixation [14]. The well-known anti-
adhesive properties of its collagen barrier to intraperito-
neal adhesions have already proven its efficacy [15–17].
Our observed recurrence rate of 3.0% is lower than
that previously reported with other mesh devices (up to
14.8% in 25months [4, 13, 18–21], up to 12% at 16
months follow-up [22–26], or up to 10% after 43 months
according to the regional cohort study from the Danish
Hernia Database [27]). It is remarkable that a follow-up
of 2 years in our studied patients did not increase the
number of recurrences, despite a final ultrasound evalu-
ation in all patients. However, it should be noted that
this study does not exclude the possibility of later recur-
rences and that the actual recurrence rate might be
slightly higher due to the number of lost to follow-up
Fig. 1 Numerical Rating Scale Pain Assessment. Patient pain levels by post-operative visit. Whiskers are drawn from quartiles (Q1 – Median – Q3
to the extreme values of the group) * indicates P < 0.05 relative to baseline
Fig. 2 Patient satisfaction by percentage at visits 1-, 6-, 12- and 24-months postoperative
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patients. In this respect, a randomized controlled trial
comparing 2 different mesh devices could reinforce the
value of these results.
As reported previously, the early wound morbidity was
low (4.0% incidence of superficial wound dehiscence)
without any evidence of mesh infection. But, as the study
is limited by the absence of a control group, no further
additional conclusions about the PCO-VP compared to al-
ternate devices or surgical mesh repair techniques can be
drawn. PCO-VP provides a potentially better outcome
than reported by Bontinck et al., who reported 3% (3/96)
of their patients had moderate or severe pain 12months
postoperative [23]; this difference might possibly be ex-
plained by their recurrence rate and less inflammatory
and foreign body reaction after implantation of the PCO-
VP [14]. In our study the excellent patient outcome is
reflected in the quality of life global CCS score, which in-
corporates the sensation, pain and movement scores.
Conclusion
The use of PCO-VP for the repair of primary umbilical
and epigastric defects yielded a low recurrence rate, low
postoperative and chronic pain, and high satisfaction rat-
ings, confirming that PCO-VP is effective for small ventral
hernia repair in the two-year term after implantation.
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